文献速递母胎医学产科

产前游离DNA筛查胎儿染色体非整倍体及微缺失/微重复综合征的性能:中国一家产前诊断中心64,482例连续病例的回顾性研究

Performance of Prenatal Cell-Free DNA Screening for Foetal Chromosome Aneuploidies and Microdeletion/Microduplication Syndromes: A Retrospective Study of 64,482 Consecutive Cases From a Prenatal Diagnosis Centre in China.
PubMed 文献 · Prenat Diagn · 2025-10-11

2017至2023年间,中国一家产前诊断中心对67,742名孕妇行cfDNA筛查,检出1,148例高风险结果,其中常见非整倍体432例、性染色体非整倍体(SCA)374例、罕见常染色体非整倍体(RAA)77例、拷贝数变异(CNV)265例。T21、T18、T13的阳性预测值(PPV)分别为82.6%、56.3%、33.9%,SCA总体PPV为45.5%,CNV为60.8%,已知微缺失/微重复综合征(MMS)为57.8%。结论认为cfDNA筛查临床效用显著,但对RAA筛查适用性有限,需全面长期表型随访。

要点

  • T21的PPV为82.6%(95% CI: 77.3%-86.9%),T18为56.3%(95% CI: 45.6%-66.7%),T13为33.9%(95% CI: 24.1%-47.3%)。
  • SCA总体PPV为45.5%(95% CI: 38.9%-52.3%),其中47,XXY最高(76.6%,95% CI: 60.6%-84.8%)。
  • CNV总体PPV为60.8%(95% CI: 51.6%-69.5%),已知MMS的PPV为57.8%(95% CI: 43.3%-71.4%)。

核心结论

  • 本研究强调产前cfDNA筛查在评估胎儿染色体异常风险方面具有显著临床效用,但其对RAA筛查的适用性仍然有限。
  • 需要全面的长期表型随访以阐明CNV的临床意义。

研究设计与样本

  • 2017年至2023年间,中国一家产前诊断中心对67,742名孕妇采用基于cfDNA的下一代测序(NGS)进行胎儿非整倍体筛查。
  • 高风险结果的孕妇被建议接受侵入性产前诊断以确认发现,并被明确提供接受或拒绝该操作的选择。

主要发现

  • 产前cfDNA筛查共识别出1,148例胎儿染色体非整倍体和/或拷贝数变异(CNV)的高风险结果,包括432例常见非整倍体、374例SCA、77例RAA和265例CNV。
  • T21的PPV为82.6%(95% CI: 77.3%-86.9%),T18为56.3%(95% CI: 45.6%-66.7%),T13为33.9%(95% CI: 24.1%-47.3%)。
  • SCA总体PPV为45.5%(95% CI: 38.9%-52.3%),CNV总体PPV为60.8%(95% CI: 51.6%-69.5%),已知MMS的PPV为57.8%(95% CI: 43.3%-71.4%)。
  • SCA中PPV最高为47,XXY(76.6%,95% CI: 60.6%-84.8%),其次为47,XXX(58.1%,95% CI: 39.3%-72.9%)、45,X(33.1%,95% CI: 26.1%-41.9%)和47,XYY(30.8%,95% CI: 15.5%-61.6%)。
  • CNV中70.97%被判定为致病性或可能致病性;研究人群中检出1例T21假阴性结果和3例母体恶性肿瘤。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Prenatal cell-free DNA (cfDNA) screening has shown high accuracy for common trisomies, but its application in screening for sex chromosome aneuploidies (SCAs), rare autosomal aneuploidies (RAAs) or microdeletion/microduplication syndromes (MMSs) requires more supportive data. METHODS: Between 2017 and 2023, a total of 67,742 pregnant women were screened for foetal aneuploidies using cfDNA-based next-generation sequencing (NGS). Pregnant women with high-risk results were recommended to undergo invasive prenatal diagnosis to confirm the findings and were explicitly offered the choice to accept or decline the procedure. RESULTS: A total of 1148 high-risk results with foetal chromosome aneuploidies and/or copy number variations (CNVs) were identified from prenatal cfDNA screening. These cases included 432 common aneuploidies, 374 SCAs, 77 RAAs, and 265 CNVs. The positive predictive values (PPVs) were 82.6% (95% CI: 77.3%-86.9%) for T21, 56.3% (95% CI: 45.6%-66.7%) for T18%, and 33.9% (95% CI: 24.1%-47.3%) for T13. The overall PPVs were 45.5% (95% CI:38.9%-52.3%) for SCAs, 60.8% (95% CI: 51.6%-69.5%) for CNVs, and 57.8% (95% CI: 43.3%-71.4%) for known MMSs. Among the SCAs, the highest PPV was observed for 47,XXY (76.6%, 95% CI: 60.6%-84.8%), followed by 47,XXX (58.1%, 95% CI: 39.3%-72.9%), 45,X (33.1%, 95% CI: 26.1%-41.9%), and 47,XYY (30.8%, 95% CI: 15.5%-61.6%). Among the CNVs, 70.97% were determined to be pathogenic or likely pathogenic. Additionally, one false-negative result for T21 and three cases of maternal malignancies were detected in our study population. CONCLUSION: This study emphasises the significant clinical utility of prenatal cfDNA screening in assessing the risk of foetal chromosomal abnormalities; however, its applicability remains limited for RAA screening. Comprehensive long-term phenotype follow-up is essential to elucidate the clinical significance of CNVs.

来源:Prenat Diagn,查看原文。版权归原作者所有。

引用

  1. Pan F, Chen X, Ying Y, et al. Performance of Prenatal Cell-Free DNA Screening for Foetal Chromosome Aneuploidies and Microdeletion/Microduplication Syndromes: A Retrospective Study of 64,482 Consecutive Cases From a Prenatal Diagnosis Centre in China. Prenat Diagn. 2025. PMID: 41074881. doi:10.1002/pd.70002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。